{"title":"The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.","authors":"A. Paschen, D. Schadendorf","doi":"10.1007/978-3-030-23765-3_6","DOIUrl":"https://doi.org/10.1007/978-3-030-23765-3_6","url":null,"abstract":"","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"60 1","pages":"169-187"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79038643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advanced Ultrasound Imaging for Patients in Oncology: DCE-US.","authors":"Nathalie Lassau","doi":"10.1007/978-3-030-42618-7_23","DOIUrl":"https://doi.org/10.1007/978-3-030-42618-7_23","url":null,"abstract":"<p><p>Neovascularization is a key stage in the growth of malignancies beyond 2-3 mm<sup>3</sup>. This neoangiogenesis is an important target for novel anticancer treatments [1], and many new antiangiogenesis or antivascular treatments aim at destroying or limiting the growth of tumor vessels [2].</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"216 ","pages":"765-771"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38092866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ultrasound Molecular Imaging of Cancer: Design and Formulation Strategies of Targeted Contrast Agents.","authors":"Alexander L Klibanov","doi":"10.1007/978-3-030-42618-7_9","DOIUrl":"https://doi.org/10.1007/978-3-030-42618-7_9","url":null,"abstract":"<p><p>Gas-filled particles (microbubbles) can be prepared and stabilized for intravascular use as contrast agents in ultrasound imaging. Microbubbles are used in clinics as blood pool contrast materials for the past two decades. Shell of these bubbles is made of biocompatible and biodegradable lipids, proteins, and/or polymers. Gas core is air, or, lately, a perfluorinated gas, poorly soluble in water and blood. Making them useful for molecular targeting and molecular imaging in oncology is accomplished by decorating the shell of these particles with targeting ligands, that will selectively bind to the specific markers of tumor vasculature. In this review we discuss the formulation strategy for microbubble preparation, the logic of bubble shell selection, coupling tools that are used for the attachment of targeting ligands, and examples of the application of gas-filled bubbles for molecular imaging in oncology.</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"216 ","pages":"319-336"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38094393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Optical and Optoacoustic Imaging Probes.","authors":"Michel Eisenblätter, Moritz Wildgruber","doi":"10.1007/978-3-030-42618-7_10","DOIUrl":"https://doi.org/10.1007/978-3-030-42618-7_10","url":null,"abstract":"<p><p>Tissue has characteristic properties when it comes to light absorption and scattering. For optical (OI) and optoacoustic imaging (OAI) these properties can be utilised to visualise biological tissue characteristics, as, for example, the oxygenation state of haemoglobin alters the optical and optoacoustic properties of the molecule.</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"216 ","pages":"337-355"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38094394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular Ultrasound Imaging.","authors":"Jasmin Baier, Anne Rix, Fabian Kiessling","doi":"10.1007/978-3-030-42618-7_15","DOIUrl":"https://doi.org/10.1007/978-3-030-42618-7_15","url":null,"abstract":"<p><p>Contrast-enhanced ultrasound (CEUS) imaging is a valuable tool for preclinical and clinical diagnostics. The most frequently used ultrasound contrast agents are microbubbles. Besides them, novel nano-sized materials are under investigation, which are briefly discussed in this chapter. For molecular CEUS, the ultrasound contrast agents are modified to actively target disease-associated molecular markers with a site-specific ligand. The most common markers for tumor imaging are related to neoangiogenesis, like the vascular endothelial growth factor receptor-2 (VEGFR2) and α<sub>v</sub>β<sub>3</sub> integrin. In this chapter, applications of molecular ultrasound to longitudinally monitor receptor expression during tumor growth, to detect neovascularization, and to evaluate therapy responses are described. Furthermore, we report on first clinical trials of molecular CEUS with VEGFR2-targeted phospholipid microbubbles showing promising results regarding patient safety and its ability to detect tumors of prostate, breast, and ovary. The chapter closes with an outlook on ultrasound theranostics, where (targeted) ultrasound contrast agents are used to increase the permeability of tumor tissues and to support drug delivery.</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"216 ","pages":"509-531"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38094399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"(Hybrid) SPECT and PET Technologies.","authors":"Teresa Nolte, Nicolas Gross-Weege, Volkmar Schulz","doi":"10.1007/978-3-030-42618-7_3","DOIUrl":"https://doi.org/10.1007/978-3-030-42618-7_3","url":null,"abstract":"<p><p>SPECT and PET are nuclear tomographic imaging modalities that visualize functional information based on the accumulation of radioactive tracer molecules. However, SPECT and PET lack anatomical information, which has motivated their combination with an anatomical imaging modality such as CT or MRI. This chapter begins with an overview over the fundamental physics of SPECT and PET followed by a presentation of the respective detector technologies, including detection requirements, principles and different detector concepts. The reader is subsequently provided with an introduction into hybrid imaging concepts, before a dedicated section presents the challenges that arise when hybridizing SPECT or PET with MRI, namely, mutual distortions of the different electromagnetic fields in MRI on the nuclear imaging system and vice versa. The chapter closes with an overview about current hybrid imaging systems of both clinical and preclinical kind. Finally, future developments in hybrid SPECT and PET technology are discussed.</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"216 ","pages":"111-133"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38097977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Circulating miRNAs as Biomarker in Cancer.","authors":"G. Andersen, J. Tost","doi":"10.1007/978-3-030-26439-0_15","DOIUrl":"https://doi.org/10.1007/978-3-030-26439-0_15","url":null,"abstract":"","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"22 1","pages":"277-298"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73153022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Vormehr, M. Diken, Ö. Türeci, U. Şahin, S. Kreiter
{"title":"Personalized Neo-Epitope Vaccines for Cancer Treatment.","authors":"M. Vormehr, M. Diken, Ö. Türeci, U. Şahin, S. Kreiter","doi":"10.1007/978-3-030-23765-3_5","DOIUrl":"https://doi.org/10.1007/978-3-030-23765-3_5","url":null,"abstract":"","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"1 1","pages":"153-167"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89746821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Applications of Circulating Tumor Cells in Breast Cancer.","authors":"E. Cobain, C. Paoletti, J. Smerage, D. Hayes","doi":"10.1007/978-3-030-26439-0_8","DOIUrl":"https://doi.org/10.1007/978-3-030-26439-0_8","url":null,"abstract":"","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"28 1","pages":"147-160"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87098725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Non-FDG PET/CT.","authors":"Egesta Lopci, Stefano Fanti","doi":"10.1007/978-3-030-42618-7_20","DOIUrl":"https://doi.org/10.1007/978-3-030-42618-7_20","url":null,"abstract":"<p><p>The major applications for molecular imaging with PET in clinical practice concern cancer imaging. Undoubtedly, 18F-FDG represents the backbone of nuclear oncology as it remains so far the most widely employed positron emitter compound. The acquired knowledge on cancer features, however, allowed the recognition in the last decades of multiple metabolic or pathogenic pathways within the cancer cells, which stimulated the development of novel radiopharmaceuticals. An endless list of PET tracers, substantially covering all hallmarks of cancer, has entered clinical routine or is being investigated in diagnostic trials. Some of them guard significant clinical applications, whereas others mostly bear a huge potential. This chapter summarizes a selected list of non-FDG PET tracers, described based on their introduction into and impact on clinical practice.</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"216 ","pages":"669-718"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38092863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
